Aligos Therapeutics Cash Flow Statement Analysis

Operating, investing, and financing activities in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for Aligos Therapeutics, Inc. (ALGS) - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Operating Activities
Net Income-131.21-87.68-96.05-128.33-108.54
Depreciation & Amortization2.623.073.683.863.33
Stock Based Compensation8.4512.6514.6913.462.98
Change in Working Capital-4.96-9.53-1.55-3.2516.06
Change in Accounts Payable0.05-2.221.72-0.31-0.13
Change in Other Working Capital-5.010.83-5.780.024.19
Other Operating Activities44.352.1712.6012.0511.68
Net Cash from Operating Activities-80.74-79.00-79.39-115.66-74.26
Investing Activities
Capital Expenditures-0.13-0.02-0.940.89-2.06
Purchases of Investments-108.1545.00-25.353.9134.82
Sales/Maturities of Investments90.0045.0078.923.9134.82
Net Cash from Investing Activities-18.2844.98-26.293.0232.76
Financing Activities
Debt Repayment-0.08-0.10-0.06-0.08-0.06
Common Stock Issued0.4418.020.2379.63155.80
Other Financing Activities0.0070.410.00-0.88-4.52
Net Cash from Financing Activities0.3688.330.1678.68192.35
Summary
Net Change in Cash-98.6754.31-105.52-33.96150.84
Cash at Beginning of Period135.7781.46186.98220.9470.10
Cash at End of Period37.11135.7781.46186.9870.10
Free Cash Flow-80.87-79.02-80.33-116.55-76.33